Back to Research

Organization profile

LeadXpro

LeadXpro is a specialist organization in structure-based drug discovery (SBDD) focused on "unlocking" membrane proteins like GPCRs, ion channels, and transporters. The company utilizes advanced biophysics, Cryo-EM, and synchrotron-based technologies to accelerate the development of novel medicines for unmet medical needs.

Villigen, SwitzerlandFounded 2015

Overview

1. Executive Summary (Confidence: High)

LeadXpro AG, founded in 2015 and headquartered at the Paul Scherrer Institute (PSI) in Switzerland, is a preeminent leader in membrane protein research. Membrane proteins are the targets for over 50% of marketed drugs, yet they are notoriously difficult to characterize due to their instability outside the cell membrane. LeadXpro has solved this "insurmountable" challenge by combining proprietary target stabilization with world-class structural biology tools, including the Swiss Free Electron Laser (SwissFEL) and advanced Cryo-EM. As of 2024, the company has established protein science for more than 100 drug targets and has moved multiple programs into the hit-to-lead stage through collaborations with companies like Cumulus Oncology and Golgi Neurosciences. In early 2026, the company entered a transformative partnership with Nuclera to integrate AI-guided workflows into its platform, further accelerating the timeline from protein sequence to structural insights.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.